Martin Brenoe
Stock Analyst at Nordea Markets
(0.63)
# 4,093
Out of 4,581 analysts
11
Total ratings
33.3%
Success rate
-15%
Average return
Main Sectors:
Stocks Rated by Martin Brenoe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: 0QIU Novo Nordisk A/S | Upgraded: Buy | kr 350.00 | kr 335.80 | +4.23% | 1 | Jun 19, 2026 | |
| ZLDPF Zealand Pharma A/S | Downgraded: Hold | n/a | $45.02 | - | 1 | Mar 6, 2026 | |
| NVO Novo Nordisk | Downgraded: Hold | n/a | $51.58 | - | 1 | Feb 24, 2026 | |
| WILLF Demant A/S | Upgraded: Buy | $51 → $35 | $43.51 | -19.44% | 3 | Feb 18, 2026 | |
| LON: 0NQC Pandora A/S | Upgraded: Buy | kr 300.00 → kr 1,200 | kr 816.59 | n/a | 3 | May 7, 2025 | |
| OSSFF Embla Medical hf. | Initiated Coverage: Buy | $5.76 | $4.15 | n/a | 1 | Jun 22, 2023 | |
| PNDRY Pandora A/S | Upgraded: Hold | n/a | $15.39 | n/a | 1 | Feb 9, 2023 |
Novo Nordisk A/S
Jun 19, 2026
Upgraded: Buy
Price Target: kr 350.00
Current: kr 335.80
Upside: +4.23%
Zealand Pharma A/S
Mar 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $45.02
Upside: -
Novo Nordisk
Feb 24, 2026
Downgraded: Hold
Price Target: n/a
Current: $51.58
Upside: -
Demant A/S
Feb 18, 2026
Upgraded: Buy
Price Target: $51 → $35
Current: $43.51
Upside: -19.44%
Pandora A/S
May 7, 2025
Upgraded: Buy
Price Target: kr 300.00 → kr 1,200
Current: kr 816.59
Upside: n/a
Embla Medical hf.
Jun 22, 2023
Initiated Coverage: Buy
Price Target: $5.76
Current: $4.15
Upside: n/a
Pandora A/S
Feb 9, 2023
Upgraded: Hold
Price Target: n/a
Current: $15.39
Upside: n/a